Jason comes to Vantis Vascular with over 20 years of experience in driving medical innovation and navigating dynamic industry trends. Jason also serves as a Board Member for Efemoral Medical, a developer of advanced interventional bioresorbable therapies. Prior to his role at Vantis, Jason was Chief Operating Officer at Venclose (acquired by BD), where he was responsible for business planning and execution. He brings a unique breadth and depth of experience building and leading lean, scalable teams and has spent the last 15 years with medical technology start-ups in the vascular space. Jason has held various operational and commercial leadership roles, including playing an instrumental role in the growth and success of Access Closure (acquired by Cardinal Health). Jason holds a Bachelor of Science in Finance degree from San Jose State University.

Dr. Fischell, M.D., FACC, MSCAI, FNAI, is a distinguished physician and Professor of Medicine, currently serving as Chief Medical Officer of Vantis Vascular. With a remarkable career spanning decades, Dr. Fischell has left an indelible mark on the medical field. Dr. Fischell’s academic journey boasts credentials from renowned institutions like Cornell University Medical College, Massachusetts General Hospital, Stanford University Hospital, and Vanderbilt University. He enjoys teaching and serves as the Program Director of the Interventional Cardiology Fellowship training program at Michigan State University, Borgess Heart Institute. He serves as a driving force behind medical innovation, as his contributions extend beyond academia. He has founded or co-founded numerous medical device companies and holds over 100 patents, revolutionizing the landscape of cardiovascular intervention. As a clinician, researcher, entrepreneur, and prolific inventor, Dr. Fischell continues to reshape cardiovascular interventions and improve patient care.

Dr. Saltiel is a distinguished cardiologist and visionary leader, currently serving as the Chief Clinical Officer at Vantis Vascular. He has comprehensive experience as an interventional cardiologist with special expertise in complex coronary interventions and structural heart disease. Based in Kalamazoo, Michigan, Dr. Saltiel serves as the Medical Director of Cardiology as well as the Chairman of the Ascension Borgess Heart Institute at Ascension Borgess Hospital. With a focus on clinical research, medical education, and medical device advancement, Dr. Saltiel serves as an Associate Clinical Professor of Medicine at both The Michigan State University College of Human Medicine and The Homer Stryker Western Michigan University School of Medicine. He is also a co-founder and general partner with the Novus Biotechnology Fund. Throughout his career, he has maintained extensive involvement in device innovation, keeping him at the forefront of modern cardiology.

Gary leverages nearly 30 years of experience in sales, marketing, and management within the medical device industry. Prior to his role at Vantis Vascular, he led Venclose (acquired by BD) in the same role. He was part of the executive team at TriReme Medical, a California-based subsidiary of QT Vascular, which develops and manufactures therapies for complex vascular disease. Gary was VP of Business Development at Sapheon (acquired by Covidien/Medtronic), a developer of closure systems for treatment of venous reflux disease. His expertise extends to Cardiovascular Systems, Fox Hollow Technologies, Pilot Cardiovascular Systems, and other innovative cardiology enterprises which were later acquired by industry giants such as C.R. Bard, Boston Scientific, Guidant, and St. Jude Medical. Gary earned his Bachelor of Arts in Communications from the University of Missouri, Columbia.

Mike has over 30 years of hands-on experience and technical management in medical device R&D and product development in start-up, medium, and large companies spanning multiple clinical indications. Before joining Vantis Vascular, Mike served as Vice President of R&D for Venclose (acquired by BD), where he was responsible for building and developing an R&D team commercializing an ablation technology for treating patients with chronic venous insufficiency. Over his career, Mike has held multiple positions of increasing responsibility including at Spirox (acquired by Stryker), Qool Therapeutics, VNUS Medical (acquired by Covidien), Guidant Corporation, Target Therapeutics, and Alcon Surgical. Mike has a Bachelor of Science in Industrial Engineering from California Polytechnic State University, San Luis Obispo, and is an inventor on over 70 issued and pending U.S. and foreign patents.

Marc brings over 30 years of experience helping technology companies in the life sciences, software, and renewable energy industries grow their businesses, raise capital, and achieve successful exits for their investors. Prior to Vantis, he was the Chief Financial Officer at Actian, where he guided the company through multiple acquisitions and integrations that quadrupled its size to over $300 million in annual revenue during his 10-year tenure. Before Actian, Marc led the finance and legal organizations that played instrumental roles in supporting the exponential growth and eventual exits at both NEXTracker (acquired by Flex) and Access Closure (acquired by Cardinal Health). Marc is a CPA and graduated from Brigham Young University with a degree in accounting and information systems.

James brings over 15 years of experience in manufacturing engineering and operations management with specific expertise in medical device design transfer and product lifecycle management. Prior to Vantis Vascular, he held positions with increasing responsibility at start-up and industry-leading companies including Venclose (acquired by BD), VNUS Medical (acquired by Covidien, now part of Medtronic), Miramar Labs (acquired by Sientra), Abbott, and Covidien (acquired by Medtronic). He brings a data-driven, lean manufacturing approach to develop business opportunities and long-term business relationships. James holds a Master of Science degree in Mechanical Engineering from San Jose State University.

With over 20 years of experience in the medical device industry, Mai-Ly brings a wealth of knowledge and expertise in navigating complex regulatory landscapes. Throughout her career, Mai-Ly has successfully managed regulatory submissions and approvals for numerous innovative medical devices, ensuring compliance with FDA, EMA, and other global regulatory requirements. She has a proven track record of fostering strong relationships with regulatory agencies and driving the implementation of robust quality systems. Before joining Vantis Vascular, Mai-Ly held various roles of increasing responsibility within regulatory and quality at Venclose (acquired by BD), Silk Road Medical (acquired by Boston Scientific), Miramar Labs (acquired by Sientra), and VNUS (acquired by Covidien/Medtronic). Mai-Ly graduated from UC Davis with a Bachelor of Science in Chemistry.